“…In addition, some novel risk factors, such as endothelin-1 levels, homocysteine (HCY) levels, erythrocyte sedimentation rate (ESR), and positive lupus anticoagulant, have been identified as risk factors of CVD for TA patients ( Table 1 ) ( 38 , 39 , 41 , 43 , 47 ). Furthermore, the TA patients who have already experienced cardiovascular complications would be at a high risk to experience CVD recomplications, which alarms the doctors to prevent poor outcomes ( 44 , 46 ). However, medications or surgical interventions could not ensure that no relapse or complications can occur in TA patients ( 2 ).…”